It's no secret that anxiety conditions and depression co-occur. In fact, most researchers agree they co-occur at least 60 percent of the time. They're so interrelated that most antidepressants are ...

Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo™ (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress BUOY-1 builds on successful ...

A year after the US Food and Drug Administration (FDA) opened the door to clinical use of lysergic acid diethylamide (LSD), US-based MindMed has launched phase 3 trials in the United States and Europe ...

Nitrous oxide, better known as laughing gas, is emerging from the dental chair and operating room as one of the most ...

For many people with major depressive disorder (MDD), the first or second antidepressant doesn't cut it. Maybe your sleep gets better. Maybe the darkest thoughts ease up. But you still slog through ...

PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo™ (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress BUOY-1 ...

BUOY-1 builds on successful Phase 1 and Phase 2a data with GlyphAllo – a novel oral prodrug of allopregnanolone and a potential first-in-class treatment for MDD Allopregnanolone has demonstrated rapid ...